Definium Therapeutics (NASDAQ:DFTX) Upgraded at Wells Fargo & Company

Definium Therapeutics (NASDAQ:DFTX) was upgraded by equities researchers at Wells Fargo & Company to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other equities research analysts have also issued reports on the company. Needham & Company LLC raised their price objective on Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Oppenheimer set a $60.00 target price on Definium Therapeutics and gave the company an “outperform” rating in a research report on Monday, June 22nd. Robert W. Baird increased their price target on Definium Therapeutics from $37.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, June 23rd. Wall Street Zen upgraded Definium Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday. Finally, Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Definium Therapeutics presently has a consensus rating of “Buy” and an average target price of $52.36.

Definium Therapeutics Stock Down 1.2%

Shares of NASDAQ:DFTX opened at $42.65 on Monday. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.15. Definium Therapeutics has a 12 month low of $7.96 and a 12 month high of $49.20. The company has a 50-day moving average price of $34.09 and a 200 day moving average price of $24.10. The company has a market cap of $4.25 billion, a price-to-earnings ratio of -17.13 and a beta of 2.20.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.23). As a group, equities research analysts predict that Definium Therapeutics will post -2.27 earnings per share for the current year.

Insiders Place Their Bets

In other Definium Therapeutics news, CEO Robert Barrow sold 29,208 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the completion of the transaction, the chief executive officer owned 1,098,246 shares in the company, valued at $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares in the company, valued at approximately $9,433,199.61. This represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 48,096 shares of company stock worth $2,165,763 over the last three months. 2.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Definium Therapeutics

A number of large investors have recently bought and sold shares of DFTX. Royal Bank of Canada grew its position in Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after acquiring an additional 6,148 shares during the last quarter. Creative Planning lifted its position in shares of Definium Therapeutics by 2.6% during the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Definium Therapeutics by 5.1% during the second quarter. JPMorgan Chase & Co. now owns 48,487 shares of the company’s stock valued at $315,000 after purchasing an additional 2,342 shares during the period. Rhumbline Advisers boosted its stake in shares of Definium Therapeutics by 6.3% during the second quarter. Rhumbline Advisers now owns 115,296 shares of the company’s stock valued at $748,000 after purchasing an additional 6,839 shares during the period. Finally, Russell Investments Group Ltd. grew its holdings in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.